Case Western Reserve University researchers unveiled a mechanistic blueprint for a next-generation cancer vaccine that pairs personalized mRNA payloads with engineered exosomes. The goal is to convert immunologically “cold” tumors into “hot” ones by reprogramming local immune responses and improving drug sensitivity. The approach focuses on using exosomes as a delivery and immune-activation vehicle alongside patient-specific mRNA design, aiming to overcome the immunosuppressive microenvironment that often blocks checkpoint inhibitors and other targeted strategies. If the preclinical rationale translates clinically, the platform could become a modular template for combining personalized RNA therapeutics with biologically engineered vesicles across tumor types that have not responded well to standard immunotherapies.